Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price objective raised by investment analysts at The Goldman Sachs Group from $105.00 to $108.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The firm currently has a "neutral" rating on the biopharmaceutical company's stock. The Goldman Sachs Group's target price suggests a potential downside of 12.06% from the stock's previous close.
Other equities analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Dbs Bank upgraded Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Cantor Fitzgerald boosted their price objective on shares of Gilead Sciences from $129.00 to $135.00 and gave the stock an "overweight" rating in a research report on Thursday, October 9th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price for the company in a report on Friday, July 25th. Finally, Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a report on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Gilead Sciences has an average rating of "Moderate Buy" and an average target price of $119.17.
Read Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Trading Up 4.2%
NASDAQ GILD opened at $122.81 on Friday. The firm's fifty day moving average is $115.22 and its two-hundred day moving average is $110.53. Gilead Sciences has a one year low of $85.60 and a one year high of $124.11. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market cap of $152.38 billion, a PE ratio of 24.46, a P/E/G ratio of 0.81 and a beta of 0.34.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the company posted $2.01 earnings per share. The business's revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.
Insider Transactions at Gilead Sciences
In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares in the company, valued at $67,692,231.75. This trade represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares of the company's stock, valued at $13,532,333.04. This represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,500 shares of company stock worth $8,281,540 in the last three months. Company insiders own 0.27% of the company's stock.
Institutional Trading of Gilead Sciences
A number of institutional investors and hedge funds have recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the first quarter worth $25,000. GoalVest Advisory LLC increased its holdings in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Activest Wealth Management raised its position in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences during the second quarter worth about $27,000. Finally, Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $29,000. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.